ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
2seventy bio Inc

2seventy bio Inc (TSVT)

2.54
-0.01
(-0.39%)
마감 18 2월 6:00AM
2.53
-0.01
(-0.39%)
시간외 거래: 9:59AM

행사 가격매수가매도가최근 가격중간 가격가격 변동가격 변동 %거래량미결제 약정최근 거래
2.500.000.000.000.000.000.00 %00-
5.000.050.050.050.050.000.00 %0279-

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

행사 가격매수가매도가최근 가격중간 가격가격 변동가격 변동 %거래량미결제 약정최근 거래
2.500.050.250.050.150.000.00 %024-
5.000.704.900.002.800.000.00 %00-

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
JTAIJet AI Inc
US$ 6.02
(133.33%)
104.48M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
WRDWeRide Inc
US$ 31.4877
(83.39%)
21.07M
INLFINLIF Limited
US$ 16.27
(80.58%)
7.68M
MBRXMoleculin Biotech Inc
US$ 2.1201
(66.94%)
136.66M
BLACBellevue Life Sciences Acquisition Corporation
US$ 3.08
(-56.31%)
425.19k
BLACUBellevue Life Sciences Acquisition Corporation
US$ 3.36
(-52.68%)
5.21k
CSAICloudastructure Inc
US$ 19.0001
(-49.58%)
1.01M
NEXNNexxen International Ltd
US$ 10.30
(-49.16%)
160.99k
BSLKBolt Projects Holdings Inc
US$ 0.6626
(-46.13%)
13.07M
CNSPCNS Pharmaceuticals Inc
US$ 0.1415
(31.26%)
480.49M
MGOLMGO Global Inc
US$ 0.7176
(-15.08%)
411.17M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
248.48M
INTCIntel Corporation
US$ 23.60
(-2.20%)
225.04M
NVDANVIDIA Corporation
US$ 138.85
(2.63%)
189.56M

TSVT Discussion

게시물 보기
Monksdream Monksdream 6 월 전
TSVT under $5
👍️0
Monksdream Monksdream 10 월 전
TSVT under $5
👍️0
Invest-in-America Invest-in-America 11 월 전
TSVT: Big (Post-M) news for this Firm & partner Bristol Myers.

"Bristol Myers, 2seventy Bios Cancer Treatment Wins FDA Committee Approval
7:04 PM ET 3/15/24 | Dow Jones
By Ben Glickman Bristol Myers Squibb and 2seventy Bio's cancer treatment showed a favorable risk-benefit profile in certain populations, according to Food and Drug Administration committee. The Oncologic Drugs Advisory Committee voted 8-3 that Abecma, a gene therapy, had a favorable profile in the treatment of the blood cancer multiple myeloma, specifically in the triple-class exposed relapsed or refractory forms of the cancer, the companies said on Friday. Bristol Myers Squibb and 2seventy said the recommendation would be considered by the FDA in its review of their supplemental Biologics License Application. The FDA hasn't assigned a new target action date for reviewing that application, the companies said. Abecma was recently approved in Japan and Switzerland for patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. Write to Ben Glickman at ben.glickman@wsj.com > Dow Jones Newswires March 15, 2024 19:04 ET (23:04 GMT)"
👍️0
Monksdream Monksdream 11 월 전
TSVT 10Q due March 5
👍️0
molee molee 1 년 전
$TSVT > A bit of "short covering" going on now ... How high ???
👍️0
Monksdream Monksdream 1 년 전
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👎️ 1
johnhancoque johnhancoque 1 년 전
2 seventy will be auctioned off in Bankruptcy court within a year. Cash on hand is 12 months or less.
👍️0
molee molee 1 년 전
C'mon man . What the heck . $2.00 now ? Really ?
👍️0